Absolute Antibody Launches New, High-Throughput Recombinant Antibody Production Service

March 5, 2020

The technology enables the rapid production of large numbers of recombinant antibodies at 80-mL scale.

Absolute Antibody, a UK-based provider of recombinant antibody products and services, has launched its FleXpress high-throughput recombinant antibody production service, which offers the flexibility to rapidly express a large number of antibodies at 80-mL scale. All production takes place at the company’s ISO-certified antibody manufacturing facility in Northeast England, according to a March 4, 2020 press release. The facility was recently expanded to increase production capacity and meet the growing demand for recombinant antibody technology.

The high-throughput recombinant antibody production service can be applied to early-stage pharmaceutical research and to conduct pilot studies on a group of therapeutic antibody candidates. It can also be used by reagent companies that have a monoclonal antibody (mAb) portfolio and that are interested in converting their collection from hybridomas to recombinant production.

Recombinant antibodies, which have long been the standard in pharmaceutical development, are growing increasingly popular for research and diagnostic applications because of their superior batch-to-batch reproducibility, antibody engineering options, and guaranteed long-term supply, Absolute Antibody reports.

The antibody production service uses Absolute Antibody’s HEXpress antibody expression platform, a serum-free, mammalian transient expression system. The system offers a faster, more affordable alternative to stable Chinese hamster ovary cell-line generation, according to the company. The proprietary system produces high-quality recombinant antibodies in any species, isotype, or format, including multispecifics and fragments. In addition, the antibodies are produced with high purity and low endotoxin levels.

The FleXpress production line can recombinantly manufacture hundreds of different antibodies per week at 80-mL scale. It joins two other production lines at the company’s antibody manufacturing facility, which also offers the option to scale to multi-gram quantities in a number of weeks.

“Absolute Antibody specializes in recombinant antibody technology, and we’ve developed a robust and reliable platform for high-throughput antibody production at relatively small scales,” said Catherine Bladen, PhD, chief operations officer, Absolute Antibody, in the company press release. “Our new production line gives our customers the flexibility to rapidly and cost-effectively test recombinant versions of many different antibodies using our proven recombinant expression technology.”

Source: Absolute Antibody